8:00 am – 8:30 am | What’s Really Up With Drug Shortages
Speaker: Serena Amouk, Clinical Pharmacotherapy Specialist, SICU, NYU Langone Health
According to a recent study by Vizient, they estimated that drug shortages are costing facilities at least $359 million per year in labor costs for implementing mitigation strategies to improve patient care. The top five drug categories with drug shortages found to have the most impact on hospitals were controlled substances, local anesthetics, crash cart drugs, antibiotics, and electrolytes. Unfortunately, 38% of hospitals reported one or more drug shortage-related medication errors. In this session we’ll examine the variety of different reasons, including manufacturing and quality issues, delays, and discontinuations and discuss how to evaluate and lessen the impacts of drug shortages.
1. Examine the underlying reasons drug shortages occur.
2. Outline approaches on for your IDN to lessen the impact of drug shortages.
3. Specify how your IDN can improve patient care by lessening the impact of drug shortages.
8:30 am – 9:00 am | Introduction to AI and Its Usefulness in Predicting and Mitigating Drug Shortages
Speaker: Jessica Daley, Vice President, HC Pharmacy and Supply Chain Commercial Services, UPMC
The promise of Artificial Intelligence (AI) is that is simplifies clinicians and administrator’s workload by performing tasks normally done by humans in less time and lower costs. One of the areas that hold unlimited promise of AIs potential is healthcare, specifically the pharmaceutical supply chain. Whether it's used to find new links between genetic codes or lessen drug shortages artificial intelligence is reinventing modern healthcare through machines that can predict, comprehend, learn and act. In this session, Jessica Daley will discuss how UPMC is using AI to predict and mitigate drug shortages throughout the UPMC system.
1. Review how one IDN is using AI to lessen the impact of drug shortages.
2. Demonstrate the power of AI and how it can impact your IDN with drug shortages.
3. Rank the priorities necessary for you to implement AI to assist you in dealing with drug shortages.
9:30 am – 10:00 am | Drug Diversion and the Practicalities
Speaker: Charles L. D’Amato, R.Ph., Supervisor Drug Diversion Prevention, Mayo Clinic Arizona
According to a 2017 report released by the Agency for Healthcare Research and Quality, the national rate of opioid-related inpatient stays (hospitalizations) increased 64.1% and the national rate of opioid-related emergency department (ED) visits increased 99.4% from 2005 to 2014. Traditionally, the approach to drug diversion prevention is driven by reports which has proven ineffective.
This session will review a comprehensive predictive analytics program that Mayo Clinic Arizona has implemented that incorporates waste retrieval and waste assay. They identified diversion in less than five days and have not had a diversion case that they didn’t initiate in past five years. They cleaned their practice by over 98% for both Anesthesia and Nursing and the model and tool is being installed corporately throughout Mayo Enterprise.
1) Describe the impact that the opioid epidemic has on hospital services.
2) Identify successful practices implemented that have reduced the rate of drug diversion.
3) Produce strategies for wide-spread adoption and implementation of these services in your IDN.
10:00 am – 10:30 am | The Impact of Track and Trace on Drug Shortages
Speaker: Michael Molby, Pharmacy Manager, Atrium Health
Since the Drug Supply Chain Security Act (DSCSA) law went into effect on November 27, 2013, much has been written about the law and its implications to various stakeholders in the US drug supply chain. Unfortunately, there are relatively few independent resources available for dispensers (specifically pharmacies) to reference when trying to understand the requirements and implications of the law. The purpose of this presentation is two-fold: 1) to provide dispensers with the information needed to implement a DSCSA compliant process, and 2) to share insights and lessons learned from one health system’s journey toward DSCSA compliance.
1. Describe the dispenser requirements under DSCSA.
2. Outline the FDA’s DSCSA implementation milestones.
3. State the critical importance of maintaining accurate DSCSA data.
10:45 am – Noon | Moderated Forum on Drug Shortages
Moderator: Susan Moravec, Consultant
Join your peers in this group-led learning activity to share your thoughts on: 1) what you got out of the morning sessions, 2) share your concerns on drug shortages, 3) ask any questions you didn’t get a chance to ask the presenters during their session, 4) share your thoughts on what your IDN is doing to combat drug shortages among other topics in the last session of the Fall IDN Summit.
1) Compare thoughts with your peers to finalize your thinking on drug shortages impact on your IDN.
2) Discuss ways to improve your plans on drug shortages.
3) Formulate your action plans concerning drug shortages.